Cassava Sciences, Inc. Announces A Potentially Significant Safety Finding Based On Interim MRI Data Which Suggest Simufilam Is Not Associated With Amyloid-Related Imaging Abnormalities; Safety Finding Based On Blinded MRI Brain Data At Week 40
Portfolio Pulse from Benzinga Newsdesk
Cassava Sciences, Inc. (NASDAQ:SAVA) announced a significant safety finding based on interim MRI brain data from Alzheimer's patients enrolled in a Phase 3 clinical trial of simufilam. The data suggests that simufilam is not associated with amyloid-related imaging abnormalities (ARIA), a known risk factor for Alzheimer's patients taking anti-amyloid antibody drugs. The safety finding is based on an independent, interim neuroradiological evaluation of brain MRIs taken at week 40 in a blinded sub-study of 180 Alzheimer's patients.
October 25, 2023 | 1:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cassava Sciences' announcement of a significant safety finding for simufilam could potentially boost investor confidence in the company and its drug candidate. The absence of association with ARIA, a known risk factor for Alzheimer's patients, could be seen as a positive development in the Phase 3 clinical trial.
The announcement of a positive safety finding for simufilam, Cassava Sciences' drug candidate, could be seen as a significant milestone in the ongoing Phase 3 clinical trial. This could potentially boost investor confidence in the company and its drug candidate, leading to a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100